Comparison
Abaloparatid vs. Lanreotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
247062-33-5
108736-35-2
Molecular weight
3960.6 g/mol
1096.34 g/mol
Half-life
1.7 h
no data
Sequence
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2no data
Mechanism of action
Abaloparatid
Abaloparatide is a synthetic analogue of the first 34 amino acids of parathyroid hormone-related protein (PTHrP). Like parathyroid hormone and teriparatide it binds the PTH-1 receptor, but the literature describes it as preferentially engaging the so-called RG conformation of the receptor, which is associated with shorter signaling duration. As for the entire drug class, intermittent receptor activation is regarded as the mechanistic basis for the stimulation of bone-forming osteoblasts observed in studies, whereas continuously elevated exposure would tend to favor bone resorption. From this binding behavior the literature derives a discussed balance between bone formation and bone resorption.
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
1
of which in humans
4
1
Effects recorded
4
2
Open conflicts
1
1
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Abaloparatid and Lanreotid?
- Abaloparatid is classified as "Research other", while Lanreotid is classified as "Research other". Abaloparatid: Abaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein (PTHrP 1-34). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis in postmenopausal women at high fracture risk. Like the related teriparatide, studies describe it as stimulating new bone formation, but it exhibits a distinct receptor-binding profile. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Abaloparatid or Lanreotid?
- The highest available evidence level is "Human RCT" for Abaloparatid and "Human RCT" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Abaloparatid and Lanreotid in Germany and the United States?
- Germany: Abaloparatid — Prescription, Lanreotid — Prescription. United States: Abaloparatid — Prescription, Lanreotid — Prescription. These are factual summaries with source and review date on the individual pages.